Coenzyme M

Generic Name: Coenzyme M

Brand Names: Uromitexan

Drug Type: Small Molecule

Chemical Formula: C_₂H_₆O_₃S_₂

CAS Number: 3375-50-6

Unique Ingredient Identifier: VHD28S0H7F

Background: Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication: Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions: Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide

Clinical Trials

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)
Chronic Lymphocytic Leukemia (CLL)
Chemotherapy-sensitive Lymphoma
Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
Acute Myelogenous Leukemia (AML)
Acute Biphenotypic Leukemia (ABL)
Acute Undifferentiated Leukemia (AUL)

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
Radiation: Total Body Irradiation (TBI) 200cGy on Day -1
Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
Drug: Busulfan
Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
Procedure: Infusion of non-T-cell depleted bone marrow on Day 0
Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: G-CSF
Drug: Pre-HCT Mesna on Days -2 and -1
Drug: Pre-HCT Mesna on Days -5 and -4
Drug: Pre-HCT Mesna on Days -6 and -5
Drug: Post-HCT Mesna

First Posted Date: 2016-06-08

Last Posted Date: 2020-12-02

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 80

Registration Number: NCT02793544

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center - Adults, New York, New York, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program, Richmond, Virginia, United States

and more 8 locations

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Phase 2

Active, not recruiting

Conditions: Myeloid Sarcoma
Chronic Myeloid Leukemia (CML)
Myelodysplastic Syndrome (MDS)
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Non-Hodgkin Lymphoma (NHL)
Juvenile Myelomonocytic Leukemia (JMML)

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Blinatumomab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: G-CSF
Drug: Melphalan
Drug: Mesna
Drug: Rituximab
Drug: Tacrolimus
Drug: Thiotepa
Biological: HPC,A Infusion
Device: CliniMACS
Drug: Sirolimus

First Posted Date: 2016-06-06

Last Posted Date: 2025-03-13

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 170

Registration Number: NCT02790515

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Phase 2

Terminated

Conditions: Locally Advanced Sarcoma

Interventions: Drug: Dexamethasone
Drug: Doxorubicin
Drug: Fosaprepitant Dimeglumine
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Mesna
Drug: Ondansetron
Other: Questionnaire Administration
Drug: Rolapitant Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2016-04-08

Last Posted Date: 2021-08-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT02732015

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Phase 2

Withdrawn

Conditions: Fibrolamellar Hepatocellular Carcinoma
Hepatocellular Carcinoma (Fibrolamellar Variant)
Hepatocellular Carcinoma

Interventions: Procedure: living related donor partial liver transplantation
Radiation: Total body irradiation
Procedure: Bone marrow transplant from same donor
Drug: Cyclophosphamide
Drug: Mesna
Drug: Filgrastim
Drug: Tacrolimus
Drug: mycophenolate mofetil
Drug: Prednisone
Drug: Antithymocyte globulin
Drug: fludarabine

First Posted Date: 2016-03-09

Last Posted Date: 2018-06-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT02702960

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Fludarabine Phosphate
Drug: Mesna
Drug: Cyclophosphamide
Radiation: Total nodal irradiation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Biological: Rituximab

First Posted Date: 2016-01-11

Last Posted Date: 2022-01-05

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 11

Registration Number: NCT02652468

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Gemcitabine
Drug: Dexamethasone
Drug: Mesna
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Selinexor
Drug: G-CSF

First Posted Date: 2015-05-07

Last Posted Date: 2025-04-15

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 129

Registration Number: NCT02436707

Locations: 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 10 locations

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1

Withdrawn

Conditions: Lymphoma
Hodgkin's Lymphoma
Non-hodgkin's Lymphoma

Interventions: Drug: Pembrolizumab
Drug: Brentuximab vedotin
Drug: Etoposide
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Rituximab

First Posted Date: 2015-04-03

Last Posted Date: 2017-06-27

Lead Sponsor: Western Regional Medical Center

Registration Number: NCT02408042

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

Phase 1

Terminated

Conditions: Stiff-Person Syndrome

Interventions: Biological: Autologous Hematopoietic Stem Cells
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Drug: Rituxan

First Posted Date: 2014-11-04

Last Posted Date: 2021-01-27

Lead Sponsor: Northwestern University

Target Recruit Count: 23

Registration Number: NCT02282514

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Phase 2

Completed

Conditions: Bone Marrow Failure Syndromes
Severe Aplastic Anemia

Interventions: Procedure: Bone marrow transplant
Drug: Thymoglobulin
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: TBI
Drug: Mesna
Drug: Tacrolimus
Drug: Mycophenolic acid mofetil

First Posted Date: 2014-08-25

Last Posted Date: 2023-03-10

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 18

Registration Number: NCT02224872

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Early Phase 1

Terminated

Conditions: Medulloblastoma

Interventions: Drug: Lomustine
Drug: Vincristine
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Mesna

First Posted Date: 2014-08-08

Last Posted Date: 2021-11-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 6

Registration Number: NCT02212574

Locations: 🇺🇸
Ann and Robert H Lurie Children's Hospital of Chicago Hematology/Oncology, Chicago, Illinois, United States
🇺🇸
Children's Hospital Colorado Center for Cancer & Blood Disorders, Aurora, Colorado, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy